Hester Biosciences Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Hester Biosciences Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Hester Biosciences shares trading at Rs.2,203 against a market capitalisation of Rs.1,840 Cr and a price-to-earnings multiple of 32.0. As a pharmaceuticals and life sciences name on the NSE and BSE, Hester Biosciences enters the Hester Biosciences Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

This Hester Biosciences Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.86 Cr revenue and Rs.17 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.

Get Free Investment Predictions and Hester Biosciences Research at Univest

About Hester Biosciences

Hester Biosciences (NSE: HESTERBIO) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings. Ahead of the Hester Biosciences Q1 Results FY27 print, the company’s most recent reported quarter (Q4 FY26) shows revenue of Rs.97 Cr and net profit of Rs.17 Cr, forming the base against which the Hester Biosciences Q1 Results FY27 estimates in this article are built. This Hester Biosciences Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Hester Biosciences Q1 FY27 Estimates

Metric	Q1 FY27E (Range)	Q1 FY26 Actual	YoY Growth
Revenue (Rs. Cr)	104-120	86	+29.5%
Net Profit / PAT (Rs. Cr)	23-29	17	+50.0%
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.2,644-2,930

Univest, a SEBI-Registered Investment Advisor, Tracks Hester Biosciences Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. CDMO Pipeline Visibility

Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Hester Biosciences’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Hester Biosciences share price target or faces renewed pressure.

2. New Product Approvals

New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Hester Biosciences’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Hester Biosciences share price target or faces renewed pressure.

3. Capacity Scale-Up

Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Hester Biosciences’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Hester Biosciences share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Hester Biosciences’s live price and Q1 FY27 result updates.

Key Risks to the Hester Biosciences Q1 Results FY27 Outlook

• Pricing pressure in key export markets, particularly the US generics segment.
• Regulatory or plant compliance issues affecting supply continuity.
• R&D and capacity expansion costs weighing on near-term profitability.

Q4 FY26 Performance Context for the Hester Biosciences Q1 Results FY27 Print

Hester Biosciences closed Q4 FY26 with revenue of Rs.97 Cr and net profit of Rs.17 Cr, a year-on-year revenue change of +29.5% and PAT change of +974.7% versus Q4 FY25. This base underpins the Hester Biosciences Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Hester Biosciences Q1 Results FY27 commentary once reported.

Technical Analysis Ahead of Hester Biosciences Q1 Results FY27

Hester Biosciences shares last traded at Rs.2,203. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Hester Biosciences Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Hester Biosciences Q1 Results FY27 trailing-growth framework points to a range of Rs.2,308-2,484 for Hester Biosciences, contingent on the Hester Biosciences Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Hester Biosciences Q1 Results FY27 view for Hester Biosciences works out to Rs.2,644-2,930, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a constructive bias is how Univest research categorises the stock heading into Hester Biosciences Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Hester Biosciences Q1 Results FY27 analysis would put Hester Biosciences in a Rs.3,019-3,415 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Hester Biosciences Q1 Results FY27 Print

• Revenue and PAT versus the Hester Biosciences Q1 Results FY27 estimate range in this preview.
• Management commentary on FY27 growth guidance and margin trajectory relevant to the Hester Biosciences Q1 Results FY27 narrative.
• Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
• Pricing pressure in key export markets, particularly the US generics segment

Conclusion on Hester Biosciences Q1 Results FY27

Hester Biosciences enters the Q1 FY27 results season trading at Rs.2,203, with the 12-month Uniresearch target range of Rs.2,644-2,930 reflecting a tracking with a constructive bias stance. Investors tracking the Hester Biosciences Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

FAQs on Hester Biosciences Q1 Results FY27

When are Hester Biosciences Q1 FY27 results expected?

Ans. Hester Biosciences’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Hester Biosciences Q1 FY27 revenue estimate?

Ans. The Uniresearch trailing-growth estimate for Hester Biosciences’s Q1 FY27 revenue is Rs.104-120 Cr, based on the Q1 FY26 base of Rs.86 Cr.

What is the Hester Biosciences share price target?

Ans. The 12-month Uniresearch estimate for Hester Biosciences share price target is Rs.2,644-2,930, based on trailing growth and current valuation multiples.

Is Hester Biosciences a good buy before Q1 FY27 results?

Ans. Hester Biosciences is tracking with a constructive bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Hester Biosciences’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.

Where can I track Hester Biosciences share price live?

Ans. Hester Biosciences share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.